Idexx Laboratories (IDXX) Stock Price, Fundamentals & Analysis

What IDXX does

Idexx Laboratories (IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E.

Key numbers explained

• 522.02 USD is the current share price, the amount you would pay for one share in the market.
• 36.3 is the trailing P/E ratio, which compares the share price to the last 12 months of earnings per share; a higher number can mean the market expects strong future growth.
• 31.2 is the forward P/E ratio, which uses expected future earnings instead of past results, helping you see whether the stock looks expensive relative to what analysts expect.
• 14.39 USD is the trailing 12-month earnings per share, the portion of the company's profit allocated to each outstanding share.
• 0% is the dividend yield, meaning the company currently pays no cash dividend relative to its share price.
• 0% is the share of earnings paid out as dividends, confirming that Idexx Laboratories (IDXX) retains all of its earnings rather than distributing them to shareholders.
• 1.54 is the beta, a measure of how much the stock tends to move compared with the overall market; a beta above 1 suggests higher volatility.
• 74.2% is the return on equity, showing how effectively the company generates profit from shareholders' equity.
• 41.18 mld. USD is the market capitalisation, the total market value of all outstanding shares, placing Idexx Laboratories (IDXX) among large-cap stocks.
• -16.8% is the price change over the last 52 weeks, indicating the stock has declined from one year ago to today.

Recent news

Recent headlines highlight questions about whether to continue holding IDXX stock, a reaffirmation of long-term growth targets, and a focus on diagnostics growth drivers including cancer testing at the Morgan Stanley Conference. Other stories cover the company's bet on an AI scribe to sell more pet diagnostics and note that IDXX trades below fair value following a 26% slide, with some analyses suggesting it could be 29% below fair value as diagnostics growth stays in focus.

What to watch

For Idexx Laboratories (IDXX), investors typically monitor diagnostic innovation and pipeline progress, as well as growth in companion animal and water-testing markets. The company's position within the S&P 500 means it can be affected by broad market movements and sector rotations. Competitive dynamics with peers such as Becton Dickinson (BDX) and Viatris (VTRS) may also influence sentiment. Regulatory changes, reimbursement policies, and macroeconomic conditions that affect healthcare spending are additional factors to observe.